Mission
CureDuchenne is dedicated to curing Duchenne muscular dystrophy (DMD) through innovative venture philanthropy that funds groundbreaking research, early diagnosis, and access to treatment, while providing education and support programs for those affected by the disease.
Basic Information
Tax-Exempt
Founded in
2003
EIN
20-0299958
Total Assets
$28.41 million
UN Sustainable Development Goals Supported
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.
Showing 3 of 4 goals
At a Glance
CureDuchenne's Family Support Program
Providing support and education to families affected by Duchenne muscular dystrophy.
Impact Report 2023
An overview of CureDuchenne's accomplishments and impact in the last year.
Upcoming Events
Join us at our various fundraising and community events.
Impact Stats
10
Years
Increased Life Expectancy
Since the inception of CureDuchenne, life expectancy for Duchenne has increased.
18
Projects
Clinical Trials Funded
18 projects funded by CureDuchenne have progressed to clinical trials.
$50M+
Dollars
Funds Raised
We’ve raised over $50 million for research, education, and care.
1st
Rank
First FDA-Approved Drug
CureDuchenne contributed early funding for the first FDA-approved Duchenne drug.
$3B
Dollars
Follow-on Funding Leveraged
Our model has leveraged over $3 billion in follow-on funding for future programs from investors and biotech companies.
Upcoming Events
Americana Manhasset Champions for Charity®
December 5, 2024
Holiday shopping benefit to support CureDuchenne.
Learn More
CAREGIVER DINNER SESSION | San Antonio, TX
December 7, 2024
A session to discuss health and wellness for Duchenne families.
Learn More
Austin Marathon | Support Tim Revell
February 16, 2025
Support Tim Revell's 20th Austin Marathon run.
Learn More
Cars, Cigars & Connections
February 22, 2025
Join us for a night of philanthropy at the Segerstrom Shelby Event Center.
Learn More
Our Programs
CureDuchenne CARES
A program to support families and individuals affected by Duchenne through educational resources and care guidance.
Learn MoreImpact Reports
MIP Score (Beta)
The MIP Score is in beta! We'd love any feedback you may have.
The MIP Score and it's methodology is purely used as a way to visualize how a nonprofits public financial data compares against others. It doesn't reflect the unique circumstances and impact that a nonprofit has.The MIP Score should never be used to say one charity is better than another.
Overall Score
66
60
/100
Program Expense Ratio
74.81%
10
/20
Program Revenue Growth
0.00%
2
/20
Leverage Ratio
0.01093
20
/20
Working Capital Ratio
3.12
16
/20
Fundraising Efficiency
1.36
12
/20
Latest Filing Data: Form 990
Fiscal Year:2022
Source:Source: Self-reported by organization
Financial Details
Revenue
| Category | Amount | Percentage |
|---|---|---|
| Contributions, Gifts, and Grants | 2.43M | 42.24% |
| Program Services | 0 | 0.00% |
| Investment Income | 362.7K | 6.31% |
| Sales of Non-Inventory Assets | -215.1K | -3.74% |
| Other Notable Sources | -32.93K | -0.57% |
| Total Revenue | 5.751M | 100.00% |
Related Nonprofits
Jacobs Institute Inc.
Med Research
Orthopedic ResearchChild Neurology Education and Research Foundation
Med Research
Orthopedic ResearchInternational Rett Syndrome Foundation
Med Research
Orthopedic ResearchHealth Effects Institute
Med Research
Orthopedic ResearchOsteogenesis Imperfecta Foundation Inc.
Med Research
Orthopedic Research